Industry concentration continues to increase, it is recommended to pay attention to generic pipeline rich leading pharmaceutical companies.

"Pharmaceutical Network Market Analysis" August 20, the third batch of national drug centralized procurement in Shanghai opened tenders.
a total of 189 enterprises participated in the procurement, resulting in 125 enterprises to be selected, 191 products to be selected, the average price reduction of selected products 53%, the highest reduction of 95%.
reported that the third batch of national drug collection announced the results of the proposed selection, drug centralized procurement is conducive to generic drug pipeline rich, fast access to approval of leading pharmaceutical companies.
it is understood that the round of collection of about 200 enterprises to participate in the tender, including more than 50 listed companies.
Among them, China Biopharmaceuticals, Yangzijiang Pharmaceuticals, Shipharma Group, Qilu Pharmaceuticals, Shanghai Pharmaceuticals, Hengrui Pharmaceuticals, Colum Pharmaceuticals, etc. are involved in the collection of more varieties of enterprises, but also domestic generic head enterprises, the industry said, some head enterprises are expected to achieve rapid release through the collection of generic drugs business.
In the industry believes that, with the normalization of production procurement into a final decision, the concentration of the generic pharmaceutical industry will continue to improve, the Chinese standard pharmaceutical companies are expected to further stabilize market share through collection, it is recommended to pay attention to the rich generic echelons, large-scale production capacity, RAW drug preparations integration of leading enterprises.
promote consistency evaluation to improve the quality of generic drugs, is the core policy of import replacement.
quality can effectively replace, so that the people trust domestic medicine.
some people pointed out that in the future in the Chinese market, can only be innovative drugs and over-evaluated generic drugs in the world.
who has the ability to go to the fore to engage in innovative drugs, who have the strength to engage in evaluation of generic drugs, who have the power to play ordinary generic drugs to the extreme.
have neither the ability, the strength nor the certain strength of the enterprise, only disappeared in the vast Red Sea.
overall, the overall strength of Hengrui Pharmaceuticals, Qilu Pharmaceuticals, etc. is still the main force of centralized procurement in the future, the same, their existence is also in line with the overall requirements of the country's generic drug replacement requirements.
At present, Hengrui Pharmaceutical's generic drug revenue accounted for more than 85%, but Hengrui deep-cultivation anti-tumor drugs, surgical anesthetics, contrast agents, major diseases and other fields, forming a rich product development pipeline, innovative drugs have been unique, research and development capabilities can not be underestimated.
the first half of this year, in the face of great challenges from the external environment, Hengrui Pharmaceuticals still adheres to the two strategies of "technological innovation" and "internationalization".
the reporting period, the Company obtained 3 batch of innovative pharmaceutical preparations and 1 batch of generic preparations.
37 clinical approvals for innovative drugs, 3 varieties of consistent evaluation approvals, and completed the consistency evaluation and declaration of 2 products.
internationalization of generic drugs, the sodium chloride injection of right meetomethyl hydrochloride was approved in the United States.
Again, such as Qilu Pharmaceuticals, in the first half of this year, the State Drug Administration approved a total of 212 drug approvals, involving 146 varieties, of which from an enterprise point of view, Qilu Pharmaceuticals became a big winner, in the first half of this year, a total of 9 generic varieties were approved for listing.
Qilu Pharmaceuticals is one of the leading domestic generic pharmaceutical enterprises, not only in the first half of this year, generic drugs were approved more products, but also generic drug consistency evaluation of many varieties of enterprises, as of June 22, 33 products have passed the consistency evaluation, of which 20 for the first domestic evaluation.
In June this year alone, Qilu Pharmaceuticals had four drugs approved for the market: Osharil platinum injections, entikawe tablets, olotad eye drops hydrochloric acid (single dose), and omythane tablets.
In accordance with the relevant national policies, through the consistency evaluation of drug varieties, quality and efficacy equivalent to the original research products, to promote consistency evaluation is to improve the quality of generic drugs, the realization of import replacement of the core policy, in the payment of medical insurance will be appropriate support, medical institutions should give priority to procurement and clinical selection, drugs through consistency evaluation, is conducive to improving the market competitiveness of the drug.
and with the normalization of belt procurement into a final decision, the concentration of the generic drug industry will continue to increase, the future generic prices will be a downward trend overall.
If there are reports that the third batch of national drug collection rules slightly adjusted, the maximum number of selected enterprises from the second batch of 6 to 8, while increasing the concentration of the industry at the same time product supply is also guaranteed.
the centralized procurement of drugs is conducive to the generic pipeline rich, fast access to approval of leading pharmaceutical enterprises, so the industry recommends to pay attention to the rich generic echelons, large-scale production capacity, raw materials pharmaceutical preparation integration of leading enterprises.
.